Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 307,564,288
  • Shares Outstanding, K 2,532,644
  • Annual Sales, $ 60,115 M
  • Annual Income, $ 365,000 K
  • 60-Month Beta 0.37
  • Price/Sales 5.12
  • Price/Cash Flow 39.61
  • Price/Book 8.11
Trade MRK with:

Options Overview Details

View History
  • Implied Volatility 22.60% ( +0.09%)
  • Historical Volatility 11.40%
  • IV Percentile 79%
  • IV Rank 63.21%
  • IV High 26.55% on 10/20/23
  • IV Low 15.81% on 02/06/24
  • Put/Call Vol Ratio 0.47
  • Today's Volume 14,453
  • Volume Avg (30-Day) 21,041
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 394,071
  • Open Int (30-Day) 377,028

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 2.12
  • Number of Estimates 8
  • High Estimate 2.24
  • Low Estimate 2.02
  • Prior Year 1.40
  • Growth Rate Est. (year over year) +51.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
119.23 +1.85%
on 03/15/24
130.24 -6.76%
on 02/23/24
-6.35 (-4.97%)
since 02/16/24
3-Month
105.24 +15.39%
on 12/20/23
130.24 -6.76%
on 02/23/24
+15.40 (+14.52%)
since 12/18/23
52-Week
99.14 +22.49%
on 10/19/23
130.24 -6.76%
on 02/23/24
+17.34 (+16.66%)
since 03/17/23

Most Recent Stories

More News
3 Cheap Dividend Stocks to Scoop Up This March

After a second straight losing week for stocks, investors in search of relative safety in the market might want to consider value-priced dividend stocks - like the three income picks we've highlighted...

KO : 60.13 (+0.42%)
DD : 73.52 (+0.12%)
BKR : 32.39 (+0.22%)
MRK : 121.44 (-0.07%)
$SPX : 5,149.42 (+0.63%)
GILD : 73.26 (-0.58%)
OC : 157.67 (-1.33%)
DOOR : 130.67 (-0.02%)
KOF : 98.28 (-0.05%)
Stocks Close Mildly Lower on Caution Ahead of Tuesday’s U.S. CPI Report

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.11%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed -0.37%. Stocks Monday traded...

$SPX : 5,149.42 (+0.63%)
SPY : 512.86 (+0.59%)
$DOWI : 38,790.43 (+0.20%)
DIA : 387.73 (+0.19%)
$IUXX : 17,985.01 (+0.99%)
QQQ : 437.48 (+0.82%)
ZNM24 : 110-005 (+0.18%)
NVDA : 884.55 (+0.70%)
AMD : 190.65 (-0.21%)
MRVL : 67.20 (+0.49%)
MU : 93.78 (+0.57%)
LRCX : 925.28 (+1.67%)
Stocks Mildly Lower on Caution Ahead of Tuesday’s U.S. CPI Report

The S&P 500 Index ($SPX ) (SPY ) is down -0.24%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.12%. Stocks are trading lower this morning...

$SPX : 5,149.42 (+0.63%)
SPY : 512.86 (+0.59%)
$DOWI : 38,790.43 (+0.20%)
DIA : 387.73 (+0.19%)
$IUXX : 17,985.01 (+0.99%)
QQQ : 437.48 (+0.82%)
ZNM24 : 110-005 (+0.18%)
NVDA : 884.55 (+0.70%)
MRVL : 67.20 (+0.49%)
AMD : 190.65 (-0.21%)
LRCX : 925.28 (+1.67%)
MU : 93.78 (+0.57%)
Have $2,500? 2 Superior Growth Stocks to Buy in 2024

These businesses can pack a punch in your portfolio over the long run.

ABBV : 178.49 (+0.34%)
MRK : 121.44 (-0.07%)
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:OCEA),(NASDAQ:LVTX),(NYSE:MRK),(NYSE:ABBV) EQNX::TICKER_END

OCEA : 4.05 (-1.70%)
ONCY : 1.0400 (+5.17%)
ONC.TO : 1.42 (+5.97%)
LVTX : 2.94 (-0.34%)
MRK : 121.44 (-0.07%)
ABBV : 178.49 (+0.34%)
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments

ONCY : 1.0400 (+5.17%)
ONC.TO : 1.42 (+5.97%)
LVTX : 2.94 (-0.34%)
MRK : 121.44 (-0.07%)
ABBV : 178.49 (+0.34%)
3 Magnificent Growth Stocks to Buy in March

These three stocks have two important common denominators: the same industry and tremendous growth prospects.

MRK : 121.44 (-0.07%)
MS : 87.96 (-0.48%)
NVO : 132.89 (+0.39%)
LLY : 762.66 (+1.13%)
MRNA : 104.26 (+0.39%)
VRTX : 411.38 (+0.91%)
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now

The futures for these two beaten-down stocks could be brighter than their recent pasts.

CRSP : 71.47 (-2.03%)
MRK : 121.44 (-0.07%)
NTLA : 27.37 (-3.29%)
MRNA : 104.26 (+0.39%)
2 Monster Stocks to Buy Without Any Hesitation

Investors can sleep easy at night with these stocks in their portfolios.

MRK : 121.44 (-0.07%)
ISRG : 392.62 (-0.92%)
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032

EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NYSE:MRK) EQNX::TICKER_END

TNXP : 0.3335 (+3.89%)
PFE : 27.72 (-0.79%)
LLY : 762.66 (+1.13%)
ABBV : 178.49 (+0.34%)
MRK : 121.44 (-0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 123.64
2nd Resistance Point 123.08
1st Resistance Point 122.26
Last Price 121.44
1st Support Level 120.87
2nd Support Level 120.31
3rd Support Level 119.49

See More

52-Week High 130.24
Last Price 121.44
Fibonacci 61.8% 118.36
Fibonacci 50% 114.69
Fibonacci 38.2% 111.02
52-Week Low 99.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar